MDT RSI

What is MDT?

Medtronic started back in 1949 in a Minneapolis garage when Earl Bakken and Palmer Hermundslie began repairing hospital equipment. Today, it is a global powerhouse headquartered in Ireland, operating a diversified business model focused on four main pillars: Cardiovascular, Medical Surgical, Neuroscience, and Diabetes. They basically dominate the space by providing high-tech solutions for chronic diseases.

Their product lineup is massive. You probably know them for the Micra, which is the world’s smallest leadless pacemaker, but they also lead in robotic-assisted surgery with the Hugo system and advanced insulin pumps like the MiniMed 780G. A huge historical milestone was Bakken’s invention of the first battery-powered external pacemaker in 1957, which literally launched the modern medtech industry. More recently, the 2015 acquisition of Covidien was a game-changer that reshaped their global footprint.

From a financial perspective, Medtronic is often seen as a steady Dividend Aristocrat. They have a track record of increasing dividends for over four decades. While they face some headwinds from supply chain issues and tough competition, their massive R&D budget—usually around $2.7 billion annually—keeps them ahead of the curve. They maintain strong cash flows and a solid balance sheet, making them a staple in many long-term portfolios.

Looking ahead to 2026, the strategy is all about fewer, bigger, and better bets. They are leaning hard into Artificial Intelligence and machine learning to make their devices smarter and more predictive. We should expect to see significant margin expansion as they finish spinning off lower-margin businesses like their Patient Monitoring and Respiratory Interventions units. By 2026, their focus on high-growth areas like structural heart and neuro-modulation should drive consistent mid-single-digit revenue growth and improved shareholder returns.

What is RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and magnitude of price changes. Developed by J. Welles Wilder, RSI ranges from 0 to 100 and helps traders identify overbought or oversold conditions in an asset.

For MDT, monitoring the RSI provides valuable insights into potential trend reversals and entry/exit points. When the RSI drops below 30, Medtronic plc is typically considered oversold, suggesting the asset may be undervalued. Conversely, an RSI above 70 indicates overbought conditions.

Understanding MDT RSI Signals

• Oversold (RSI below 30): When MDT RSI falls below 30, it suggests the asset may have been sold off excessively and could be due for a bounce. This is often viewed as a potential buying opportunity, though it's important to consider other factors and not rely solely on RSI.
• Overbought (RSI above 70): An RSI above 70 indicates MDT may be overbought, potentially signaling a pullback or consolidation phase. Traders often use this as a signal to take profits or wait for better entry points.
• Divergences: When MDT price makes new highs or lows but RSI doesn't confirm these moves, it can signal weakening momentum and a possible trend reversal.

Daily vs Weekly RSI for MDT

This page displays both daily and weekly RSI for MDT. The daily RSI responds quickly to short-term price movements, making it useful for day traders and swing traders. The weekly RSI provides a broader perspective on momentum trends, helping longer-term investors identify major oversold or overbought conditions.

By analyzing both timeframes together, you can better understand Medtronic plc's momentum at multiple levels and make more informed trading decisions.

Historical RSI Oversold Analysis

Above, we track historical instances when MDT RSI dropped below 30 (oversold territory). Reviewing these past oversold levels helps identify patterns and understand how Medtronic plc has historically responded to oversold conditions. Many traders use these historical reference points to gauge potential support levels and timing for entry positions.